Compare Jumia Technologies AG - ADR (JMIA) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Sana Biotechnology Inc — how do they compare? Jumia Technologies AG - ADR trades at $6.28 (market cap $865.90M), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Jumia Technologies AG - ADR and Sana Biotechnology Inc are close in size by market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,695,227). Which is the better fit depends on your goals — on Pluang, investors hold Jumia Technologies AG - ADR for 28 Days and Sana Biotechnology Inc for 23 Days on average.
| JMIA | SANA | |
|---|---|---|
Market Cap | $865.90M | $836.71M |
Volume | 1,695,227 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $5.92 |
52-Week Low | $5.69 | $2.68 |
Typical Hold Time | 28 Days | 23 Days |
Enterprise Value | $831.54M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA stock trades at $6.48, down 3.86% today, with a bearish technical outlook from moving averages. The company reported Q2 2026 revenue growth and narrowing losses, with a path to EBITDA breakeven by Q4 2026. Analyst consensus is bullish with a $12.00 price target, but the stock faces headwinds from persistent negative earnings and high valuation multiples.
The investment case hinges on JMIA's operational improvements and capital infusion, but risks include sustained cash burn and competitive pressures in African e-commerce. Upside potential exists if profitability targets are met, yet the stock remains speculative given its financial losses and volatile trading pattern.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
